Last reviewed · How we verify

Micronized dHACM — Competitive Intelligence Brief

Micronized dHACM (Micronized dHACM) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biologic tissue graft / Regenerative medicine product. Area: Wound Care / Regenerative Medicine.

phase 3 Biologic tissue graft / Regenerative medicine product Wound Care / Regenerative Medicine Biologic Live · refreshed every 30 min

Target snapshot

Micronized dHACM (Micronized dHACM) — MiMedx Group, Inc.. Micronized dehydrated human amnion/chorion membrane (dHACM) provides a biologic scaffold that promotes tissue regeneration and wound healing through growth factors and extracellular matrix components.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Micronized dHACM TARGET Micronized dHACM MiMedx Group, Inc. phase 3 Biologic tissue graft / Regenerative medicine product

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biologic tissue graft / Regenerative medicine product class)

  1. MiMedx Group, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Micronized dHACM — Competitive Intelligence Brief. https://druglandscape.com/ci/micronized-dhacm. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: